Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Payables (2016 - 2025)

Historic Payables for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to $6.6 million.

  • Standard Biotools' Payables fell 3941.97% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year decrease of 3941.97%. This contributed to the annual value of $5.0 million for FY2024, which is 4533.35% down from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' Payables is $6.6 million, which was down 3941.97% from $7.3 million recorded in Q2 2025.
  • Over the past 5 years, Standard Biotools' Payables peaked at $13.1 million during Q1 2024, and registered a low of $5.0 million during Q4 2024.
  • Moreover, its 5-year median value for Payables was $9.3 million (2022), whereas its average is $9.5 million.
  • In the last 5 years, Standard Biotools' Payables tumbled by 5119.44% in 2023 and then skyrocketed by 11510.89% in 2024.
  • Standard Biotools' Payables (Quarter) stood at $10.6 million in 2021, then decreased by 25.35% to $7.9 million in 2022, then grew by 16.7% to $9.2 million in 2023, then tumbled by 45.33% to $5.0 million in 2024, then skyrocketed by 31.1% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $7.3 million for Q2 2025, and $11.8 million during Q1 2025.